

New Products - Bydureon

Bydureon (**exenatide**) is an extended release microsphere formulation of exenatide. Exenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that exhibits several antihyperglycaemic actions of GLP-1. Exenatide suppresses glucagon secretion which is known to be inappropriately elevated in type 2 diabetes. Exenatide is indicated for the treatment of type 2 diabetes mellitus in combination with metformin or sulfonylurea or metformin + sulfonylurea in patients who have not achieved adequate glycaemic control. Exenatide is contraindicated in patients with end-stage renal disease or severe renal impairment (creatinine clearance < 30 mL/min). Bydureon is available as a once weekly powder for injection supplied in a carton containing 4 single dose kits.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.